LIFE Aug 2022 7.500 call
| Previous Close | 0.3500 |
| Open | 0.3500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 7.50 |
| Expire Date | 2022-08-19 |
| Day's Range | 0.3500 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 78 |
- Simply Wall St.
Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year
Quite a few insiders have dramatically grown their holdings in aTyr Pharma, Inc. ( NASDAQ:LIFE ) over the past 12...
- GlobeNewswire
aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment
Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and cancer. SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that new
- GlobeNewswire
aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
Conference hosted by The Ohio State University’s Center for RNA Biology to showcase latest advancements in tRNA biology SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase biology platform, today announced that Leslie A. Nangle, Ph.D., Vice President, Research at aTyr, will present at the International 28th tRNA Conference, which is schedu
